Condition: B-cell Mediated Autoimmune Disorders · Sponsor: TG Therapeutics, Inc.
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
This description comes directly from the study's public registry record.
TG Therapeutics Clinical Support Team · 1-877-575-8489 · clinicalsupport@tgtxinc.com
Always discuss trial participation with your own doctor first.
| TG Therapeutics Investigational Trial Site | La Jolla, California, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Ann Arbor, Michigan, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Omaha, Nebraska, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | New York, New York, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Rochester, New York, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Cleveland, Ohio, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Columbus, Ohio, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680037